Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 8Melanoma 6Glioblastoma 5Uterine Cervical Neoplasms 4Gliosarcoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Rectal Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Colonic Neoplasms 3Brain Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Astrocytoma 2Vulvar Neoplasms 1Virus Diseases 1Vipoma 1

Interventions

veliparib 1tipifarnib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Neoplasm × Immunoglobulin G × Clear all
NCT01749384 2017-10-12

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡